8-K
filed October 10, 2024, 7:59 PM ET
ticker BNGO
CIK 0001411690
earnings
confidence high
sentiment negative
materiality 0.75
Bionano lowers Q3 revenue guidance to $6.5-6.8M from $7.9-8.9M; cash $23.3M
Bionano Genomics, Inc.
2024-Q3 EPS reported
-$1.34
revenue$22,613,000
- Preliminary Q3 revenue $6.5-6.8M, down from prior guidance of $7.9-8.9M.
- Cash and restricted cash ~$23.3M as of Sep 30; $11.4M restricted.
- Revenue miss driven by strategic shift away from new OGM system placements and sector headwinds.
- Potential material impairments and charges pending completion of end-of-period review.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001140361-24-043244
- form_type
- 8-K
- ticker
- BNGO
- cik
- 0001411690
- company_name
- Bionano Genomics, Inc.
- filed_at
- 2024-10-10T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:08.380671+00:00
- generated_at
- 2026-05-30T16:30:46.146947+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- negative
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001140361-24-043244
- json_url
- https://secwatch.observer/filing/0001140361-24-043244.json
- markdown_url
- https://secwatch.observer/filing/0001140361-24-043244.md
- text_url
- https://secwatch.observer/filing/0001140361-24-043244.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1411690/000114036124043244/0001140361-24-043244-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1411690/000114036124043244/ef20037106_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
CRDO
Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs
Credo Technology Group Holding Ltd
June 1, 2026, 4:08 PM ET
earnings
Items 2.02, 5.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
RMCF
Rocky Mountain Chocolate Factory Q4 revenue down 24% to $6.8M; net loss per share widens to $0.38
Rocky Mountain Chocolate Factory, Inc.
June 1, 2026, 9:15 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
SAIC
SAIC Q1 adj EPS $3.23 beats $1.92; raises FY adj EBITDA and EPS guidance
Science Applications International Corp
June 1, 2026, 6:55 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
FNGR
FingerMotion FY2026 revenue down 32% to $24.1M; net loss widens to $7.0M
FingerMotion, Inc.
May 29, 2026, 5:12 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.